Is Crop Life Scienc overvalued or undervalued?

As of 3 September 2025, Crop Life Science's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics, with a PE ratio of 14.76, an EV to EBITDA of 7.99, and a ROCE of 12.65%. Compared to its peers, Crop Life Science's valuation appears reasonable; for instance, P I Industries is very expensive with a PE of 35.41, while UPL is attractive with a PE of 35.84.
In the context of its industry, Crop Life Science's PEG ratio stands at 1.54, suggesting that it is priced in line with its growth expectations. Notably, its EV to Sales ratio of 0.63 is lower than that of its peers, reinforcing the notion that it is fairly valued. Additionally, while the stock has underperformed the Sensex over the past year with a return of -8.06% compared to the Sensex's -2.23%, its year-to-date performance of 13.66% indicates some recovery potential. Overall, Crop Life Science is fairly valued in the current market environment.